Looks like you’re on the UK site. Choose another location to see content specific to your location
Daiichi Sankyo reports positive data from new edoxaban study
Daiichi Sankyo has announced positive data from a prespecified subgroup analysis of the phase III Hokusai-VTE study of its anticoagulant therapy edoxaban.
It was found that patients with either a history of cancer or with active cancer treated with the once-daily factor Xa-inhibitor had a numerically lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared to warfarin.
Daiichi Sankyo's also had a lower incidence of clinically relevant bleeding compared to warfarin in cancer patients. These findings were consistent with results from the wider study population of 8,292 patients.
Dr Glenn Gormley, senior executive officer and global head of research and development at Daiichi Sankyo, said: "Daiichi Sankyo is committed to help clinicians understand potential treatment strategies for diverse patient populations with VTE."
The drug is currently approved only in Japan, where it is sold under the name Lixiana. It remains in phase III clinical development in other parts of the world.
Daiichi Sankyo plans to submit new drug applications for edoxaban for VTE by the first quarter of 2014 in the US, Japan and Europe.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard